Randomized controlled trials (RCTs) are considered the gold standard for assessing treatment efficacy. However, sampling bias can affect the generalization of results to routine clinical practice. Here we assessed whether patients with lupus nephritis (LN) seen in routine clinical practice would have satisfied entry criteria to the major published RCTs in LN. Methods: A systematic literature search from January 1974 to May 2015 was carried out, identifying all RCTs investigating LN induction treatment. Patients diagnosed with proliferative or membranous LN between 1995 and 2013 were identified from the Barts Lupus Centre database; baseline characteristics were compared with each RCT’s entry criteria to assess hypothetical inclusion or exclu...
Introduction: Lupus Nephritis occurred in approximately 50% of Systemic Lupus Erythematosus patients...
BACKGROUND: A criticism of Randomized Controlled Trials (RCTs) in primary care is that they lack ext...
Background: Lupus nephritis (LN) is present in over 50% of patients with systemic lupus erythematosu...
Randomized controlled trials (RCT) are the optimal study design to answer intervention questions. Th...
Background: Lupus nephritis accounts for similar to 1% of patients starting dialysis therapy. Treatm...
Objective To quantify how well phase III randomised clinical trials in both SLE and lupus nephritis ...
The heterogeneity of lupus poses a signifi cant challenge for clinical trial design. The pleomorphic...
BackgroundTo reduce treatment variability and facilitate comparative effectiveness studies, the Chil...
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with diverse manifestations. Alt...
Mycophenolate mofetil (MMF) is an immunosuppressant drug being used for induction and maintenance of...
Purpose: We used the Cochrane systematic review to analyze the effectiveness and safety of rituximab...
Journal Article; Observational Study; Research Support, Non-U.S. Gov't;The aim of the study was to p...
BACKGROUND: In this systematic review of randomized controlled trials (RCTs), we assess the benefits...
ObjectiveMost clinical trials for systemic lupus erythematosus (SLE) study the efficacy and safety o...
Background: Patients with proliferative lupus nephritis are at risk of frequent relapses. Whether lo...
Introduction: Lupus Nephritis occurred in approximately 50% of Systemic Lupus Erythematosus patients...
BACKGROUND: A criticism of Randomized Controlled Trials (RCTs) in primary care is that they lack ext...
Background: Lupus nephritis (LN) is present in over 50% of patients with systemic lupus erythematosu...
Randomized controlled trials (RCT) are the optimal study design to answer intervention questions. Th...
Background: Lupus nephritis accounts for similar to 1% of patients starting dialysis therapy. Treatm...
Objective To quantify how well phase III randomised clinical trials in both SLE and lupus nephritis ...
The heterogeneity of lupus poses a signifi cant challenge for clinical trial design. The pleomorphic...
BackgroundTo reduce treatment variability and facilitate comparative effectiveness studies, the Chil...
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with diverse manifestations. Alt...
Mycophenolate mofetil (MMF) is an immunosuppressant drug being used for induction and maintenance of...
Purpose: We used the Cochrane systematic review to analyze the effectiveness and safety of rituximab...
Journal Article; Observational Study; Research Support, Non-U.S. Gov't;The aim of the study was to p...
BACKGROUND: In this systematic review of randomized controlled trials (RCTs), we assess the benefits...
ObjectiveMost clinical trials for systemic lupus erythematosus (SLE) study the efficacy and safety o...
Background: Patients with proliferative lupus nephritis are at risk of frequent relapses. Whether lo...
Introduction: Lupus Nephritis occurred in approximately 50% of Systemic Lupus Erythematosus patients...
BACKGROUND: A criticism of Randomized Controlled Trials (RCTs) in primary care is that they lack ext...
Background: Lupus nephritis (LN) is present in over 50% of patients with systemic lupus erythematosu...